ATE70717T1 - Vermehrung der antigenimmunogenizitaet. - Google Patents

Vermehrung der antigenimmunogenizitaet.

Info

Publication number
ATE70717T1
ATE70717T1 AT87304005T AT87304005T ATE70717T1 AT E70717 T1 ATE70717 T1 AT E70717T1 AT 87304005 T AT87304005 T AT 87304005T AT 87304005 T AT87304005 T AT 87304005T AT E70717 T1 ATE70717 T1 AT E70717T1
Authority
AT
Austria
Prior art keywords
antigen
cells
monoclonal antibody
targeting
specific
Prior art date
Application number
AT87304005T
Other languages
English (en)
Inventor
Brian Harold Barber
George Carayannotis
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Application granted granted Critical
Publication of ATE70717T1 publication Critical patent/ATE70717T1/de

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6056Antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87304005T 1986-05-06 1987-05-05 Vermehrung der antigenimmunogenizitaet. ATE70717T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868610983A GB8610983D0 (en) 1986-05-06 1986-05-06 Enhancement of antigen immunogenicity
EP87304005A EP0245078B1 (de) 1986-05-06 1987-05-05 Vermehrung der Antigenimmunogenizität

Publications (1)

Publication Number Publication Date
ATE70717T1 true ATE70717T1 (de) 1992-01-15

Family

ID=10597389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87304005T ATE70717T1 (de) 1986-05-06 1987-05-05 Vermehrung der antigenimmunogenizitaet.

Country Status (6)

Country Link
US (1) US4950480A (de)
EP (1) EP0245078B1 (de)
JP (1) JPH0674210B2 (de)
AT (1) ATE70717T1 (de)
DE (1) DE3775458D1 (de)
GB (1) GB8610983D0 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US5173293A (en) * 1989-02-23 1992-12-22 Becton Dickinson And Company Anti-T-cell antibodies as adjuvants
GB8907310D0 (en) * 1989-03-31 1989-05-17 Medical Res Council Heteroconjugates
CA2015515C (en) 1990-01-03 1999-12-07 Jean-Marie Saint-Remy Pharmaceutical compositions containing antigen-antibody complexes and uses therefor
AU667460B2 (en) * 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
US6248332B1 (en) 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
US5107060A (en) * 1990-10-17 1992-04-21 Mobil Oil Corporation Thermal cracking of mercury-containing hydrocarbon
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US5686078A (en) * 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
US5928647A (en) 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
BR9608481A (pt) * 1995-06-07 2000-10-31 Connaught Lab Anticorpos quiméricos para administração de antìgenos a células selecionadas do sistema imunológico.
CA2223577A1 (en) 1995-06-07 1996-12-19 Connaught Laboratories Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
ATE399022T1 (de) * 1995-10-20 2008-07-15 Univ Nebraska Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
JP2000503003A (ja) * 1995-12-22 2000-03-14 イムノメディクス,インコーポレイテッド 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
WO1997024447A1 (en) * 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
ES2193240T3 (es) * 1996-05-15 2003-11-01 Altarex Inc Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
FR2759296B1 (fr) * 1997-02-07 1999-04-09 Commissariat Energie Atomique Complexe non-covalent comprenant au moins un anticorps et un element de liaison aux immunoglobulines associe a une substance active, son procede de preparation et ses applications
US20020025315A1 (en) * 1998-01-14 2002-02-28 Naveen N. Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
DE10296942T5 (de) * 2001-03-21 2004-11-18 Altarex Corp., Edmonton Therapeutische Zusammensetzung, welche die Immunitätsreaktion verändert
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
AU2002363861A1 (en) * 2001-11-30 2003-06-10 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an intigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
AU2002231655A1 (en) * 2001-11-30 2003-06-10 Crucell Holland B.V. Antigen presenting cell targeting conjugate an antigen presenting cell contacted with such conjugate their use for vaccination or as medicament and methods for their production or generation
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
AU2004209644A1 (en) * 2003-02-03 2004-08-19 Palo Alto Institute Of Molecular Medicine Cell-killing molecules and methods of use thereof
AU2004278748B2 (en) * 2003-09-29 2008-09-11 The Regents Of The University Of California Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration
EP2139993A2 (de) * 2007-04-27 2010-01-06 Dow Global Technologies Inc. Verbesserte herstellung und in-vivo-synthese löslicher und rekombinanter virusähnlicher partikel in ikosaeder-form
WO2012156430A1 (en) * 2011-05-17 2012-11-22 Trion Research Gmbh Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400376A (en) * 1979-03-27 1983-08-23 National Research Development Corporation Immunological preparations
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
EP0142905A2 (de) * 1983-03-30 1985-05-29 Bio-Response Inc. Therapeutisches Mittel für die Behandlung von Krankheiten wie Krebs
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
JPS6072826A (ja) * 1983-09-26 1985-04-24 バイオ−レスポンス・インコ−ポレ−テツド 疾患細胞の生体内治療物質

Also Published As

Publication number Publication date
DE3775458D1 (de) 1992-02-06
EP0245078A3 (en) 1989-07-12
GB8610983D0 (en) 1986-06-11
EP0245078A2 (de) 1987-11-11
EP0245078B1 (de) 1991-12-27
US4950480A (en) 1990-08-21
JPS6345228A (ja) 1988-02-26
JPH0674210B2 (ja) 1994-09-21

Similar Documents

Publication Publication Date Title
ATE70717T1 (de) Vermehrung der antigenimmunogenizitaet.
ATE463255T1 (de) Künstliche t-helferzell-epitope als immunstimulatoren für synthetische peptidimmunogene
DE3588022D1 (de) Pre-S-Gen kodierte Hepatitis-B immunogene Peptide, Vakzine, Diagnostika und synthetische lipidische Bläschenträger.
DE60117164D1 (de) Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
DK174416B1 (da) Oligopeptider, immunogene konjugater heraf med et antigen samt vacciner indeholdende disse konjugater
Thraenhart et al. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man
DE3666529D1 (en) Canine parvovirus vaccines
Jemmerson et al. Mapping antigenic sites on proteins: Implications for the design of synthetic vaccines.
ATE302016T1 (de) Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind
WO1999013907A3 (en) Methods to improve immunogenicity of antigens and specificity of antibodies
O'meara et al. Recombinant vaccines against ovine footrot
WO1998001558A3 (en) Protein and peptide vaccines for inducing mucosal immunity
EP0303309A3 (en) A genus-specific listeria antigen identified by monoclonal antibodies
Tabatabai et al. Characterization of salt-extractable protein antigens from Brucella abortus by crossed immunoelectrophoresis and isoelectricfocusing
ATE258986T1 (de) Sekretorischer rekombinanter bcg impfstoff gegen aids
ATE284897T1 (de) Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen
Plotkin A hundred years of vaccination: the legacy of Louis Pasteur
Hachimura et al. Relative positioning of the T cell and B cell determinants on an immunogenic peptide: its influence on antibody response
GB2314560A (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparations and use
FI894048A0 (fi) Menetelmä Pseudomonas aeruginosa-infektioita vastaan vaikuttavien valmisteiden sekä immunoglobuliini-G-pitoisten, Pseudomonas aeruginosa-bakteeria vastaan vaikuttavien valmisteiden tuottamiseksi
Mythili et al. Immunogenecity of a Brucella abortus S19 glyco-conjugate vaccine consisting of lipo-polysaccharide and outer membrane protein in cattle calves
IT1189295B (it) Composizione antigenica sintetica e procedimento per la sua preparazione

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time